Key result
TNF-α antagonism with etanercept is unlikely to be a beneficial therapeutic strategy in patients with acute myocardial infarction, as plasma TNF-α concentrations increased following treatment.
Why the study?
Does TNF-α antagonism provide a beneficial therapeutic strategy in patients with acute myocardial infarction?
Does TNF-α antagonism provide a beneficial therapeutic strategy in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
This letter highlights that TNF-α antagonism with etanercept is unlikely to be beneficial in acute myocardial infarction and may increase plasma TNF-α concentrations.
To the Editor Tumour necrosis factor-α (TNF-α) has been implicated in the development of acute myocardial infarction. The mechanisms of TNF-α on endothelial function and platelet activation in patients with acute myocardial infarction are still unclear. A recent article by Padfield et al 1 demonstrated that TNF-α antagonism is unlikely to be a beneficial therapeutic strategy in patients with acute myocardial infarction. And plasma TNF-α concentrations increased in all patients following etanercept.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2013) conducted a letter in acute myocardial infarction. TNF-α antagonism (etanercept) was evaluated. TNF-α antagonism with etanercept is unlikely to be a beneficial therapeutic strategy in patients with acute myocardial infarction, as plasma TNF-α concentrations increased following treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: